At a glance
CDC works with partners in Tajikistan to strengthen the country's public health and clinical systems. CDC delivers quality HIV testing and treatment services and responds to emerging public health threats.
Background
The partnership between the U.S. Centers for Disease Control and Prevention (CDC) and the Government of Tajikistan began in 1995. Its aim is to strengthen the country’s capacity to detect, prevent, and respond to public health threats. In 2010, CDC began implementing activities supported through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
CDC helps Tajikistan achieve HIV epidemic control by supporting the Ministry of Health’s Republican AIDS Center and Republican Narcology Center (RNC). This support helps implement interventions and activities for HIV surveillance and prevention, including medication-assisted therapy (MAT) for injecting drug users. Other areas include HIV counseling and testing, HIV care and treatment, and HIV laboratory strengthening.
CDC works to improve quality and availability of HIV prevention and treatment for people at higher risk of HIV and people living with HIV/AIDS. To do this, CDC strengthens public health system capacities to implement HIV surveillance, prevention, care, and treatment programs.
CDC supports scaling-up effective HIV prevention services for the most at-risk populations, especially groups who are disproportionally affected by HIV.
Download CDC Tajikistan's Fact Sheet
HIV and TB data
HIV/AIDS
Estimated HIV Prevalence (Ages 15-49)
Estimated AIDS Deaths (Age≥15)
Estimated Orphans Due to AIDS
Reported Number Receiving Antiretroviral Therapy (Age≥15)
Tuberculosis (TB)
Estimated TB Incidence
TB Patients with Known HIV-Status who are HIV-Positive
TB Treatment Success Rate
Key activities and accomplishments
HIV testing and prevention
In 2022, CDC actively supported the Tajikistan government to implement targeted evidence-based HIV testing strategies, including HIV index- and self-testing. CDC supports the Republican AIDS Center to develop national treatment guidelines and calculate a sufficient supply of antiretroviral drugs. This includes those used to prevent HIV infection like pre-exposure prophylaxis (PrEP).
HIV treatment
Ninety-four percent of new HIV cases found with CDC’s assistance initiated antiretroviral therapy (ART). Within 7 days of diagnosis, 92 percent of them started ART. Median time from diagnosis to ART initiation went from 12 to 5 days (Tajikistan Electronic HIV Case Management System (EHCMS), 2022).
In 2022, CDC supported 47 facilities in three regions to provide ART for 5,791 PLHIV, with 95 percent virally suppressed. In 2022, 669 HIV-positive patients started ART in CDC-supported areas for the first time (PEPFAR Monitoring, Evaluation, & Reporting, 2022). CDC also provided technical assistance (TA) to Tajikistan. TA increased viral load suppression to 95 percent in three of the highest HIV burden areas (PEPFAR Monitoring, Evaluation, & Reporting, 2022).
HIV surveillance and reporting
All HIV/AIDS centers are reporting on 100 percent of key indicators through the national EHCMS developed by CDC. This system allows for collection and analysis of patient and summary level data for improved clinical and program management (Tajikistan EHCMS, 2022).
In 2022, CDC in collaboration with the Republican AIDS Center, started implementing HIV treatment resistance surveillance. This provided timely details on patients who are resistant to available HIV treatment regimens. The data will be used to adjust policies and practices for improved patient outcomes.
In 2022, CDC also supported bio-behavioral population surveys. These surveys provided information on the burden and risk of HIV, access to services, and risk-behaviors. Populations of interest were men who have sex with men (MSM), people who inject drugs (PWID), and female sex workers (FSW). The final results from this survey have been disseminated and are being used to plan program implementation.
Medication-assisted (MAT) services
CDC continues to work with the RNC to provide comprehensive MAT services to people who inject drugs in three MAT clinics. These activities include dispensing of Opioid Substitution Therapy, HIV testing, and integrated care for patients who are positive for HIV. It also includes activities for viral hepatitis, tuberculosis (TB), as well as providing psychosocial support.
Laboratory strengthening
CDC's TA to HIV/AIDS labs helps develop and implement laboratory quality management systems for certification under international lab standard ISO 15189.
Resources
Support for CDC's global HIV and TB efforts.
Our success is built on the backbone of science and strong partnerships.